

... 119), H128 (ATCC HTB 120); and the breast carcinoma cell line DU4475 (ATCC HTB 123), which have been deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209. Preferred antigens are the human erythroleukemia cell line OCIM1.

At page 13, replace the second paragraph with the following:

The preferred monoclonal antibodies of the present invention are those designated SR-1, deposited as BA7.3C.9 with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, USA on April 4 1991, and given the Accession Number HB10716.

In the claims:

Please cancel Claim 21 without prejudice.

Please add the following new claim:

26. A method of modifying sensitivity of cells containing a stem cell factor receptor to cell cycle-specific chemotherapeutic agents comprising administering to the cells a monoclonal antibody or fragment thereof, which binds to an epitope on a receptor recognized by human stem cell factor, in an amount sufficient to inhibit the binding of stem cell factor to the receptor or to decrease the growth and development of the cells, thereby modifying the sensitivity of the cells to cell cycle-specific chemotherapeutic agents.